Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 8/2016

01-07-2016 | Original Article

The reproducibility and prognostic value of serial measurements of heart rate response to regadenoson during myocardial perfusion imaging

Authors: Efstathia Andrikopoulou, Wael A. AlJaroudi, Ayman Farag, Davis Lester, Hiren Patel, Ami E. Iskandrian, Fadi G. Hage

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2016

Login to get access

Abstract

Purpose

The heart rate response (HRR, percentage change from baseline) to regadenoson during myocardial perfusion imaging (MPI) can provide incremental prognostic value in patients with known or suspected coronary artery disease. Our purpose was to evaluate the variability and prognostic value of HRR on serial measurements.

Methods

We studied 648 consecutive patients (61 ± 11 years, 48 % with diabetes) who underwent two regadenoson MPI studies (16 ± 9 months between studies). HRR <30 % was defined as abnormal. All-cause mortality was determined by chart review and verified using the US Social Security Death Master File.

Results

HRR was well correlated between the two studies (intraclass correlation coefficient 0.72, 95 % CI 0.67 – 0.76) with no systematic bias (mean difference 0.88 %, p = 0.2) or proportional bias (p = 0.5) by Bland-Altman analysis in all patients and in those with normal MPI on both studies. Of the 308 patients (48 %) with normal baseline HRR (HRR-1), 33 % had developed a blunted HRR on the second MPI study (HRR-2). Older age, male gender, end-stage renal disease, and abnormal baseline left ventricular ejection fraction were independent predictors of a new-onset abnormal HRR. During a mean follow-up of 2.4 ± 1.2 years, 55 patients (8.5 %) died. Patients with a blunted HRR-1 had increased mortality risk irrespective of their HRR-2 (p = 0.9, log-rank test). Among patients with normal HRR-1, a blunted HRR-2 was an independent predictor of all-cause mortality beyond clinical and traditional MPI data (hazard ratio 2.83, 95 % CI 1.14 – 7.03). Finally, patients with a normal HRR-1 and HRR-2 had the lowest event rate, while those with any abnormal HRR had an increased risk of death (hazard ratio 2.5, 95 % CI 1.2 – 5.4).

Conclusion

There was good correlation in the HRR to regadenoson on serial measurements without systematic or proportional biases. Patients with consistently normal HRR had the best prognosis.
Literature
1.
go back to reference Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation. 2003;108:1404–18.CrossRefPubMed Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation. 2003;108:1404–18.CrossRefPubMed
2.
go back to reference Hage FG, Ghimire G, Lester D, Mckay J, Bleich S, El-Hajj S, et al. The prognostic value of regadenoson myocardial perfusion imaging. J Nucl Cardiol. 2015;22:1214–21.CrossRefPubMed Hage FG, Ghimire G, Lester D, Mckay J, Bleich S, El-Hajj S, et al. The prognostic value of regadenoson myocardial perfusion imaging. J Nucl Cardiol. 2015;22:1214–21.CrossRefPubMed
3.
go back to reference Hachamovitch R, Berman DS, Kiat H, Cohen I, Lewin H, Amanullah A, et al. Incremental prognostic value of adenosine stress myocardial perfusion single-photon emission computed tomography and impact on subsequent management in patients with or suspected of having myocardial ischemia. Am J Cardiol. 1997;80:426–33.CrossRefPubMed Hachamovitch R, Berman DS, Kiat H, Cohen I, Lewin H, Amanullah A, et al. Incremental prognostic value of adenosine stress myocardial perfusion single-photon emission computed tomography and impact on subsequent management in patients with or suspected of having myocardial ischemia. Am J Cardiol. 1997;80:426–33.CrossRefPubMed
4.
go back to reference Shaw LJ, Hage FG, Berman DS, Hachamovitch R, Iskandrian A. Prognosis in the era of comparative effectiveness research: where is nuclear cardiology now and where should it be? J Nucl Cardiol. 2012;19:1026–43.CrossRefPubMed Shaw LJ, Hage FG, Berman DS, Hachamovitch R, Iskandrian A. Prognosis in the era of comparative effectiveness research: where is nuclear cardiology now and where should it be? J Nucl Cardiol. 2012;19:1026–43.CrossRefPubMed
5.
go back to reference Hage FG, Dean P, Bhatia V, Iqbal F, Heo J, Iskandrian AE. The prognostic value of the heart rate response to adenosine in relation to diabetes mellitus and chronic kidney disease. Am Heart J. 2011;162:356–62.CrossRefPubMed Hage FG, Dean P, Bhatia V, Iqbal F, Heo J, Iskandrian AE. The prognostic value of the heart rate response to adenosine in relation to diabetes mellitus and chronic kidney disease. Am Heart J. 2011;162:356–62.CrossRefPubMed
6.
go back to reference Hage FG, Dean P, Iqbal F, Heo J, Iskandrian AE. A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging. J Nucl Cardiol. 2011;18:1086–94.CrossRefPubMed Hage FG, Dean P, Iqbal F, Heo J, Iskandrian AE. A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging. J Nucl Cardiol. 2011;18:1086–94.CrossRefPubMed
7.
go back to reference Hage FG, Wackers FJ, Bansal S, Chyun DA, Young LH, Inzucchi SE, et al. The heart rate response to adenosine: a simple predictor of adverse cardiac outcomes in asymptomatic patients with type 2 diabetes. Int J Cardiol. 2013;167:2952–7.CrossRefPubMed Hage FG, Wackers FJ, Bansal S, Chyun DA, Young LH, Inzucchi SE, et al. The heart rate response to adenosine: a simple predictor of adverse cardiac outcomes in asymptomatic patients with type 2 diabetes. Int J Cardiol. 2013;167:2952–7.CrossRefPubMed
8.
go back to reference AlJaroudi W, Campagnoli T, Fughhi I, Wassouf M, Ali A, Doukky R. Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease. J Nucl Cardiol. 2015. doi:10.1007/s12350-015-0234-0. AlJaroudi W, Campagnoli T, Fughhi I, Wassouf M, Ali A, Doukky R. Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease. J Nucl Cardiol. 2015. doi:10.​1007/​s12350-015-0234-0.
10.
go back to reference Iskandrian AE, Hage FG, Shaw LJ, Mahmarian JJ, Berman DS. Serial myocardial perfusion imaging: defining a significant change and targeting management decisions. JACC Cardiovasc Imaging. 2014;7:79–96.CrossRefPubMed Iskandrian AE, Hage FG, Shaw LJ, Mahmarian JJ, Berman DS. Serial myocardial perfusion imaging: defining a significant change and targeting management decisions. JACC Cardiovasc Imaging. 2014;7:79–96.CrossRefPubMed
11.
go back to reference El-Hajj S, AlJaroudi WA, Farag A, Bleich S, Manaoragada P, Iskandrian AE, et al. Effect of changes in perfusion defect size during serial regadenoson myocardial perfusion imaging on cardiovascular outcomes in high-risk patients. J Nucl Cardiol. 2016;23:101–12.CrossRefPubMed El-Hajj S, AlJaroudi WA, Farag A, Bleich S, Manaoragada P, Iskandrian AE, et al. Effect of changes in perfusion defect size during serial regadenoson myocardial perfusion imaging on cardiovascular outcomes in high-risk patients. J Nucl Cardiol. 2016;23:101–12.CrossRefPubMed
12.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.CrossRef
13.
go back to reference Henzlova MJ, Cerqueira MD, Hansen CL, Taillefer R, Yao SS. ASNC imaging guidelines for nuclear cardiology procedures: stress protocols and tracers. J Nucl Cardiol. 2009;16:331. doi:10.1007/s12350-009-9062-4. Henzlova MJ, Cerqueira MD, Hansen CL, Taillefer R, Yao SS. ASNC imaging guidelines for nuclear cardiology procedures: stress protocols and tracers. J Nucl Cardiol. 2009;16:331. doi:10.​1007/​s12350-009-9062-4.
14.
go back to reference Al Jaroudi W, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol. 2009;54:1123–30.CrossRefPubMed Al Jaroudi W, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol. 2009;54:1123–30.CrossRefPubMed
15.
go back to reference Ficaro EP, Lee BC, Kritzman JN, Corbett JR. Corridor4DM: the Michigan method for quantitative nuclear cardiology. J Nucl Cardiol. 2007;14:455–65.CrossRefPubMed Ficaro EP, Lee BC, Kritzman JN, Corbett JR. Corridor4DM: the Michigan method for quantitative nuclear cardiology. J Nucl Cardiol. 2007;14:455–65.CrossRefPubMed
16.
go back to reference Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su HT, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med. 1995;36:2138–47.PubMed Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su HT, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med. 1995;36:2138–47.PubMed
17.
go back to reference Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, et al. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J. 2009;157:771–6.CrossRefPubMed Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, et al. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J. 2009;157:771–6.CrossRefPubMed
18.
19.
go back to reference Myocardial Study Market Guide, January–June 2012. Malvern, PA: Arlington Medical Resources, Inc; 2012. Myocardial Study Market Guide, January–June 2012. Malvern, PA: Arlington Medical Resources, Inc; 2012.
20.
go back to reference Lexiscan. Northbrook, IL: Astellas Pharma US; 2015. Lexiscan. Northbrook, IL: Astellas Pharma US; 2015.
21.
go back to reference Ben Bouallegue F, Roubille F, Lattuca B, Cung TT, Macia JC, Gervasoni R, et al. SPECT myocardial perfusion reserve in patients with multivessel coronary disease: correlation with angiographic findings and invasive fractional flow reserve measurements. J Nucl Med. 2015;56:1712–7.CrossRefPubMed Ben Bouallegue F, Roubille F, Lattuca B, Cung TT, Macia JC, Gervasoni R, et al. SPECT myocardial perfusion reserve in patients with multivessel coronary disease: correlation with angiographic findings and invasive fractional flow reserve measurements. J Nucl Med. 2015;56:1712–7.CrossRefPubMed
22.
go back to reference Katz JS, Ruisi M, Giedd KN, Rachko M. Assessment of transient ischemic dilation (TID) ratio in gated SPECT myocardial perfusion imaging (MPI) using regadenoson, a new agent for pharmacologic stress testing. J Nucl Cardiol. 2012;19:727–34.CrossRefPubMed Katz JS, Ruisi M, Giedd KN, Rachko M. Assessment of transient ischemic dilation (TID) ratio in gated SPECT myocardial perfusion imaging (MPI) using regadenoson, a new agent for pharmacologic stress testing. J Nucl Cardiol. 2012;19:727–34.CrossRefPubMed
23.
go back to reference Lester D, El-Hajj S, Farag AA, Bhambhvani P, Tauxe L, Heo J, et al. Prognostic value of transient ischemic dilation with regadenoson myocardial perfusion imaging. J Nucl Cardiol. 2015. doi:10.1007/s12350-015-0272-7 Lester D, El-Hajj S, Farag AA, Bhambhvani P, Tauxe L, Heo J, et al. Prognostic value of transient ischemic dilation with regadenoson myocardial perfusion imaging. J Nucl Cardiol. 2015. doi:10.​1007/​s12350-015-0272-7
24.
go back to reference AlJaroudi W, Aggarwal H, Venkataraman R, Heo J, Iskandrian AE, Hage FG. Impact of left ventricular dyssynchrony by phase analysis on cardiovascular outcomes in patients with end-stage renal disease. J Nucl Cardiol. 2010;17:1058–64.CrossRefPubMed AlJaroudi W, Aggarwal H, Venkataraman R, Heo J, Iskandrian AE, Hage FG. Impact of left ventricular dyssynchrony by phase analysis on cardiovascular outcomes in patients with end-stage renal disease. J Nucl Cardiol. 2010;17:1058–64.CrossRefPubMed
25.
go back to reference AlJaroudi W, Alraies MC, Menon V, Brunken RC, Cerqueira MD, Jaber WA. Predictors and incremental prognostic value of left ventricular mechanical dyssynchrony response during stress-gated positron emission tomography in patients with ischemic cardiomyopathy. J Nucl Cardiol. 2012;19:958–69.CrossRefPubMed AlJaroudi W, Alraies MC, Menon V, Brunken RC, Cerqueira MD, Jaber WA. Predictors and incremental prognostic value of left ventricular mechanical dyssynchrony response during stress-gated positron emission tomography in patients with ischemic cardiomyopathy. J Nucl Cardiol. 2012;19:958–69.CrossRefPubMed
26.
go back to reference Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther. 2006;316:695–702.CrossRefPubMed Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther. 2006;316:695–702.CrossRefPubMed
27.
go back to reference Iqbal FM, Al Jaroudi W, Sanam K, Sweeney A, Heo J, Iskandrian AE, et al. Reclassification of cardiovascular risk in patients with normal myocardial perfusion imaging using heart rate response to vasodilator stress. Am J Cardiol. 2013;111:190–5.CrossRefPubMed Iqbal FM, Al Jaroudi W, Sanam K, Sweeney A, Heo J, Iskandrian AE, et al. Reclassification of cardiovascular risk in patients with normal myocardial perfusion imaging using heart rate response to vasodilator stress. Am J Cardiol. 2013;111:190–5.CrossRefPubMed
28.
go back to reference Bellam N, Veledar E, Dorbala S, Di Carli MF, Shah S, Eapen D, et al. Prognostic significance of impaired chronotropic response to pharmacologic stress Rb-82 PET. J Nucl Cardiol. 2014;21:233–44.CrossRefPubMed Bellam N, Veledar E, Dorbala S, Di Carli MF, Shah S, Eapen D, et al. Prognostic significance of impaired chronotropic response to pharmacologic stress Rb-82 PET. J Nucl Cardiol. 2014;21:233–44.CrossRefPubMed
29.
go back to reference Williams BA, Merhige ME. Comparing changes in severe versus mild perfusion defect size in patients who underwent serial rubidium-82 positron emission tomography myocardial perfusion imaging. Am J Cardiol. 2014;114:1512–7.CrossRefPubMed Williams BA, Merhige ME. Comparing changes in severe versus mild perfusion defect size in patients who underwent serial rubidium-82 positron emission tomography myocardial perfusion imaging. Am J Cardiol. 2014;114:1512–7.CrossRefPubMed
30.
go back to reference Shaw LJ, Cerqueira MD, Brooks MM, Althouse AD, Sansing VV, Beller GA, et al. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. J Nucl Cardiol. 2012;19:658–69.CrossRefPubMedPubMedCentral Shaw LJ, Cerqueira MD, Brooks MM, Althouse AD, Sansing VV, Beller GA, et al. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. J Nucl Cardiol. 2012;19:658–69.CrossRefPubMedPubMedCentral
31.
go back to reference Farzaneh-Far A, Phillips HR, Shaw LK, Starr AZ, Fiuzat M, O'Connor CM, et al. Ischemia change in stable coronary artery disease is an independent predictor of death and myocardial infarction. J Am Coll Cardiol Img. 2012;5:715–24.CrossRef Farzaneh-Far A, Phillips HR, Shaw LK, Starr AZ, Fiuzat M, O'Connor CM, et al. Ischemia change in stable coronary artery disease is an independent predictor of death and myocardial infarction. J Am Coll Cardiol Img. 2012;5:715–24.CrossRef
32.
go back to reference Zellweger MJ, Maraun M, Osterhues HH, Keller U, Muller-Brand J, Jeger R, et al. Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy. JACC Cardiovasc Imaging. 2014;7:1001–10.CrossRefPubMed Zellweger MJ, Maraun M, Osterhues HH, Keller U, Muller-Brand J, Jeger R, et al. Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy. JACC Cardiovasc Imaging. 2014;7:1001–10.CrossRefPubMed
Metadata
Title
The reproducibility and prognostic value of serial measurements of heart rate response to regadenoson during myocardial perfusion imaging
Authors
Efstathia Andrikopoulou
Wael A. AlJaroudi
Ayman Farag
Davis Lester
Hiren Patel
Ami E. Iskandrian
Fadi G. Hage
Publication date
01-07-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3380-y

Other articles of this Issue 8/2016

European Journal of Nuclear Medicine and Molecular Imaging 8/2016 Go to the issue